#PRLD

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! PM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

PM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ALTS 51% OTM
2. #ASPI 45% OTM
3. #RIVN 38% OTM
4. #TSLA 37% OTM
5. #PRLD 36% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

PM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ALTS, #ASPI, #RIVN, #PRLD, #PSTG

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations! AM Top Unusual

🚀 Institutions taking big swings on #UnusualOptionsActivity with short expirations!

AM Top Unusual Activity from 🔥 INSIDERFINANCE.COM 🔥
1. #ONDS 53% OTM
2. #ALTS 51% OTM
3. #RIVN 38% OTM
4. #PRLD 36% OTM
5. #AMD 35% OTM

#OptionFlow #OptionsTrading #Trading

0 0 0 0

1 month ago

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expir

🎯 #UnusualOptionsActivity trade ideas! Strong census from institutions on #options with short expirations.

AM Algo #TradeIdea from 🔥 INSIDERFINANCE.COM 🔥
#ONDS, #ALTS, #RIVN, #PRLD, #AMD

#OptionFlow #OptionsTrading #Trading

0 0 0 0

Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs First disclosure of PRT12396, a JAK2V617F-selective JH2 inhibitor demonstrates disease modifying potential in myeloproliferative neoplasms PRT12396 has completed GLP toxicology studies and is on track for IND filing in the first quarter 2026 First disclosure of a mutant calreticulin (mCALR)

3 months ago

#PRLD Prelude Therapeutics Presents Data at the 2025 ASH Annual Meeting from its Myeloproliferative Neoplasm (MPN) Programs

www.stocktitan.net/news/PRLD/prelude-therap...

0 0 0 0

Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update Lead candidate from mutant selective JAK2V617F JH2 inhibitor program advancing with IND filing expected in the first quarter of 2026 Lead candidate from oral KAT6A selective degrader program advancing with IND filing expected in mid-2026 Preclinical data from JAK2V617F JH2 inhibitor program and

4 months ago

#PRLD Prelude Therapeutics Reports Third Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/PRLD/prelude-therap...

0 0 0 0

Small Cap Strategist

@smcapstrategist.bsky.social

4 months ago

Most Searched, Tuesday November 4, 2025 – Crystal Equity Research

Most searched small-cap stocks, Tue Nov 4th - #HIVE #PRLD #FUBO #LAC #DENN #RR #NVTS #RXRX #SRPT #IHRT #DNN #ONDS #PLUG #HTZ #INDP #HRTG #FNV #CMBM #BTCS #BBAI - More: crystalequityresearch.com/most-searche... - #smallcap

0 0 0 0

Prelude Therapeutics Announces Strategic Business Update Prelude Therapeutics (NASDAQ: PRLD) announced an exclusive option agreement with Incyte on a previously undisclosed JAK2V617F mutant selective JH2 inhibitor, prioritized its KAT6A selective degrader program for ER+ breast cancer, and paused its SMARCA2 degrader clinical development.The Incyte deal includes an upfront payment of $35M, a $25M equity investment, and up to $100M if the option is exercised; Prelude retains program ownership until exercise. As of Oct 31, 2025 Prelude had ~$52M cash and will receive $60M at close; cash runway is expected into 2027 or potentially into Q3 2028 if Incyte exercises the option. Prelude will report Q3 2025 results and hold a call on Nov 12, 2025.

4 months ago

#PRLD Prelude Therapeutics Announces Strategic Business Update

www.stocktitan.net/news/PRLD/prelude-therap...

0 0 0 0

Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting Prelude Therapeutics (Nasdaq: PRLD) announced publication of two abstracts accepted for oral presentation at the ASH 67th Annual Meeting, December 6-9, 2025 in Orlando.The abstracts report preclinical data for two discovery programs: orally bioavailable JAK2V617F JH2 mutant-selective inhibitors showing mutant-specific inhibition, normalization of blood counts and spleen size in JAK2VF mouse models and selective reduction of JAK2VF progenitors; and mCALR-targeted DACs delivering a CDK9 degrader that selectively eliminates CALR-mutant MPN progenitors while sparing healthy CD34+ cells.

4 months ago

#PRLD Prelude Therapeutics Announces Publication of Abstracts for Presentation at the American Society of Hematology 67th Annual Meeting

www.stocktitan.net/news/PRLD/prelude-therap...

0 0 0 0

Prelude's Novel Oral Cancer Drug Reaches 7th Dose Level as Company Streamlines Pipeline Focus Prelude's oral SMARCA2 degrader PRT7732 progresses to 125mg dose cohort for aggressive cancers. Company reports $31.2M Q2 loss while maintaining runway into 2026. See pipeline updates.

7 months ago

#PRLD Prelude Therapeutics Reports Second Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/PRLD/prelude-therap...

0 0 0 0

Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update Prelude Therapeutics (NASDAQ: PRLD) reported Q1 2025 financial results and pipeline updates. The company completed enrollment for PRT3789 monotherapy and docetaxel combination trials, with results expected in H2 2025. Their oral SMARCA2 degrader PRT7732 Phase 1 study is progressing rapidly. Financial highlights include $103.1M cash position extending runway into Q2 2026. Q1 2025 saw increased R&D expenses of $28.8M (vs $27.4M in Q1 2024) and decreased G&A expenses of $5.8M (vs $6.9M). Net loss was $32.1M ($0.42 per share). The company is advancing multiple programs including SMARCA2 degraders for SMARCA4-mutated cancers, KAT6A degraders, and precision ADCs, with several key milestones expected in 2025.

10 months ago

#PRLD Prelude Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update

www.stocktitan.net/news/PRLD/prelude-therap...

0 0 0 0

Prelude Reveals Breakthrough Cancer Data: Two Novel Drug Programs Achieve Complete Tumor Regression New preclinical data shows Prelude's KAT6A degraders eliminated breast and lung cancer tumors, while SMARCA2 program advances in Phase 2. See full results.

10 months ago

#PRLD Prelude Announces Presentations at 2025 AACR Annual Meeting

www.stocktitan.net/news/PRLD/prelude-announ...

0 0 0 0

The Insiders Fund Hedge Fund Guy

@insomniachedgefund.bsky.social

11 months ago

Insider Buying 03-28-25 Stagflation is the Game. Confidence has been Shattered The market as measured by the S&P 500 shed 1.53% last month. The dollar was down, gold up. There seems […]

🔍 INSIDER BUY ALERT: Prelude Therapeutics $PRLD
📊 Krishna Vaddi, CEO, purchased 675,000 shares at $0.69 per share, investing $467,438 on March 25, 2025.
Too small of a developmental biotech for me.
Read the full analysis: bit.ly/4217ckk
#InsiderBuying #PRLD #Biotech #DevelopmentalBiotech #SmallCap

0 0 0 0